Findings

What do systematic reviews say?

3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%

Intervention not reported

Soreness on day 2 Scale from: 0 to 100. · people doing unaccustomed exercise

1 finding from 1 review

Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Low

Intervention not reported

Soreness on day 1 Scale from: 0 to 100. · people doing unaccustomed exercise

1 finding from 1 review

Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 127 participants
Low

Intervention not reported

Soreness on day 2 Scale from: 0 to 100. · people doing unaccustomed exercise

1 finding from 1 review

Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 158 participants
Low

Intervention not reported

Soreness on day 1 Scale from: 0 to 100. · people doing unaccustomed exercise

1 finding from 1 review

Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 197 participants
Low

Intervention not reported

Soreness on day 2 Scale from: 0 to 100. · people doing unaccustomed exercise

1 finding from 1 review

Stretching to prevent or reduce muscle soreness after exercise 2011 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 198 participants
Low

SPECIALISED TEAM vs usual care

Service use: 1. Average number of days in hospital per month ‐ by about 24 months · people with psychosis

1 finding from 1 review

Early intervention for psychosis 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 547 participants
Moderate

Intervention not reported

Creatine phosphate 1g/day · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Low

Intervention not reported

Creatine 20g/day for 6 weeks · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Low

Intervention not reported

Creatine 20g/day for 10 days · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Low

Intervention not reported

Creatinine phosphate 1g/day for 6 months · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Low

Intervention not reported

Creatinine phosphate 1g/day for 3 months · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Low

Factor Xa inhibitors vs Anticoagulants

All causes of mortality at 30 days · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.9 [0.8, 1.01]
4 studies · 27976 participants
High

Factor Xa inhibitors vs Anticoagulants

All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.98 [0.82, 1.18]
2 studies · 6760 participants
High

Factor Xa inhibitors vs Anticoagulants

All causes of mortality at 30 days ‐ Enoxaparin · Anticoagulants in ACS

Factor Xa inhibitors leads to lower all causes of mortality at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.85 [0.73, 0.98]
2 studies · 21216 participants
High

Factor Xa inhibitors vs Anticoagulants

Major bleeding · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).

2 findings from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.01 [0.98, 1.04]
2 studies · 20404 participants
High
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
1 study · 326 participants
High

Factor Xa inhibitors vs Anticoagulants

Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS

Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).

1 finding from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.02 [1.01, 1.02]
1 study · 20078 participants
High

Factor Xa inhibitors vs Anticoagulants

Minor bleeding · Anticoagulants in ACS

Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).

3 findings from 1 review

Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.7 [0.14, 3.39]
2 studies · 20404 participants
High
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 1.76 [0.52, 5.94]
1 study · 326 participants
Moderate
Factor Xa inhibitors for acute coronary syndromes 2011 · Cochrane Headline outcomes only
RR 0.34 [0.28, 0.43]
1 study · 20078 participants
High

Primary analyses ERAS vs conventional

Length of hospital stay · patients with colorectal surgery

1 finding from 1 review

Fast track surgery versus conventional recovery strategies for colorectal surgery 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 237 participants
Very low

Intervention vs control

60‐day mortality ‐ Aprotinin versus control · Patients with liver transplantation.

It is very uncertain whether intervention changes 60‐day mortality ‐ Aprotinin versus control compared with control (very low certainty).

1 finding from 1 review

Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
RR 0.52 [0.18, 1.45]
3 studies · 280 participants
Very low

Intervention vs control

60‐day mortality ‐ Tranexamic acid versus control · Patients with liver transplantation.

It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus control compared with control (very low certainty).

1 finding from 1 review

Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
RR 0.55 [0.17, 1.76]
3 studies · 139 participants
Very low